Insider transactions

EDGAR

BlossomHill Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
7 transactions, 1,573,900 shares
Sum of shares × price per share: 25,181,900
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–43 of 43

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-10 Filed 2026-08-12ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
Acquired (A)1,039,996——1,039,996Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000784 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
Acquired (A)1,049,283——2,089,279Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000784 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)625,00016.00
10,000,000

Derived: shares × price per share. Exact value 10000000.00.

2,714,279Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000784 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (1,039,996)
Disposed (D)1,039,9960—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000784 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (1,049,283)
Disposed (D)1,049,2830—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000784 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12GORDON CARL L Director
C

Conversion of derivative security

Common Stock
Acquired (A)1,039,996——1,039,996Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000785 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12GORDON CARL L Director
C

Conversion of derivative security

Common Stock
Acquired (A)1,049,283——2,089,279Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000785 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12GORDON CARL L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)625,00016.00
10,000,000

Derived: shares × price per share. Exact value 10000000.00.

2,714,279Indirect (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000785 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12GORDON CARL L Director
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (1,039,996)
Disposed (D)1,039,9960—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000785 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12GORDON CARL L Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (1,049,283)
Disposed (D)1,049,2830—0Indirect (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  • F3 These securities are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000785 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,599,993——1,599,993Indirect (I) See footnotesNo
F1, F2, F3, F4
  • F1 Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).
  • F2 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F3 Cormorant Asset Management, LP (Cormorant) serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the Master Fund), Cormorant Private Healthcare Fund III, LP (Fund III), Cormorant Private Healthcare Fund V, LP (Fund V) and Cormorant Private Healthcare Fund VI, LP (Fund VI). Cormorant Global Healthcare GP, LLC (GP LLC), Cormorant Private Healthcare GP III, LLC (GP III), Cormorant Private Healthcare GP V, LLC (GP V) and Cormorant Private Healthcare GP VI, LLC (GP VI) serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  • F4 Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,701,541——3,301,534Indirect (I) See footnotesNo
F5, F2, F6, F3, F4
  • F5 Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.
  • F2 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F6 Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
  • F3 Cormorant Asset Management, LP (Cormorant) serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the Master Fund), Cormorant Private Healthcare Fund III, LP (Fund III), Cormorant Private Healthcare Fund V, LP (Fund V) and Cormorant Private Healthcare Fund VI, LP (Fund VI). Cormorant Global Healthcare GP, LLC (GP LLC), Cormorant Private Healthcare GP III, LLC (GP III), Cormorant Private Healthcare GP V, LLC (GP V) and Cormorant Private Healthcare GP VI, LLC (GP VI) serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  • F4 Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)312,50016
5,000,000

Derived: shares × price per share. Exact value 5000000.

3,614,034Indirect (I) See footnotesNo
F7, F8, F3, F4
  • F7 The shares purchased are beneficially owned by Master Fund.
  • F8 Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
  • F3 Cormorant Asset Management, LP (Cormorant) serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the Master Fund), Cormorant Private Healthcare Fund III, LP (Fund III), Cormorant Private Healthcare Fund V, LP (Fund V) and Cormorant Private Healthcare Fund VI, LP (Fund VI). Cormorant Global Healthcare GP, LLC (GP LLC), Cormorant Private Healthcare GP III, LLC (GP III), Cormorant Private Healthcare GP V, LLC (GP V) and Cormorant Private Healthcare GP VI, LLC (GP VI) serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  • F4 Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
C

Conversion of derivative security

Derivative security: Series A Preferred Stock — underlying Common Stock (1,599,993)
Disposed (D)1,599,993——0Indirect (I) See footnotesNo
F2, F1, F3, F4
  • F2 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F1 Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).
  • F3 Cormorant Asset Management, LP (Cormorant) serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the Master Fund), Cormorant Private Healthcare Fund III, LP (Fund III), Cormorant Private Healthcare Fund V, LP (Fund V) and Cormorant Private Healthcare Fund VI, LP (Fund VI). Cormorant Global Healthcare GP, LLC (GP LLC), Cormorant Private Healthcare GP III, LLC (GP III), Cormorant Private Healthcare GP V, LLC (GP V) and Cormorant Private Healthcare GP VI, LLC (GP VI) serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  • F4 Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (1,701,541)
Disposed (D)1,701,541——0Indirect (I) See footnotesNo
F2, F5, F3, F4
  • F2 Each share of Series A Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F5 Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.
  • F3 Cormorant Asset Management, LP (Cormorant) serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the Master Fund), Cormorant Private Healthcare Fund III, LP (Fund III), Cormorant Private Healthcare Fund V, LP (Fund V) and Cormorant Private Healthcare Fund VI, LP (Fund VI). Cormorant Global Healthcare GP, LLC (GP LLC), Cormorant Private Healthcare GP III, LLC (GP III), Cormorant Private Healthcare GP V, LLC (GP V) and Cormorant Private Healthcare GP VI, LLC (GP VI) serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  • F4 Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Liptak Vincent Paul Officer: General Counsel
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,20016
35,200

Derived: shares × price per share. Exact value 35200.

111,412Direct (D) No— Open filing 0002143905-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Liptak Vincent Paul Officer: General Counsel
C

Conversion of derivative security

Common Stock
Acquired (A)22,687——22,687Indirect (I) By Walter T. Liptak Revocable TrustNo
F1, F2
  • F1 Each share of Series B Preferred Stock (the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the Trust) and has voting and dispositive power over the securities held by the Trust.
Open filing 0002143905-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Liptak Vincent Paul Officer: General Counsel
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (22,687)
Disposed (D)22,687——0Indirect (I) By Walter T. Liptak Revocable TrustNo
F1, F2
  • F1 Each share of Series B Preferred Stock (the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the Trust) and has voting and dispositive power over the securities held by the Trust.
Open filing 0002143905-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Schmid John P. Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)6,00016
96,000

Derived: shares × price per share. Exact value 96000.

6,000Direct (D) No— Open filing 0001478916-26-000015 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Agrawal Sundeep Director
C

Conversion of derivative security

Common Stock
Acquired (A)578,524——578,524Indirect (I) By Brahma BlossomHill Partners, LLCNo
F1, F2
  • F1 Each share of Series B Preferred Stock (the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The securities are held of record by Brahma BlossomHill Partners, LLC (Brahma Partners). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001840599-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Agrawal Sundeep Director
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (578,524)
Disposed (D)578,524——0Indirect (I) By Brahma BlossomHill Partners, LLCNo
F1, F2
  • F1 Each share of Series B Preferred Stock (the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The securities are held of record by Brahma BlossomHill Partners, LLC (Brahma Partners). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001840599-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,600,682——1,600,682Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)113,435——1,714,117Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)124,779——124,779Indirect (I) By RongShan, LLCNo
F1, F3
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F3 The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Derivative security: Series Angel Preferred Stock — underlying Common Stock (1,600,682)
Disposed (D)1,600,682——0Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (113,435)
Disposed (D)113,435——0Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (124,779)
Disposed (D)124,779——0Indirect (I) By RongShan, LLCNo
F1, F3
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F3 The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Keyes Jason A Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)70016
11,200

Derived: shares × price per share. Exact value 11200.

700Direct (D) No— Open filing 0001678152-26-000003 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)1,600,682——1,600,682Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)113,435——1,714,117Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Common Stock
Acquired (A)124,779——124,779Indirect (I) By RongShan, LLCNo
F1, F3
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F3 The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Derivative security: Series Angel Preferred Stock — underlying Common Stock (1,600,682)
Disposed (D)1,600,682——0Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (113,435)
Disposed (D)113,435——0Indirect (I) By The Li and Cui Family TrustNo
F1, F2
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F2 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the Trust) and have voting and dispositive power over the securities held by the Trust.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
C

Conversion of derivative security

Derivative security: Series B Preferred Stock — underlying Common Stock (124,779)
Disposed (D)124,779——0Indirect (I) By RongShan, LLCNo
F1, F3
  • F1 Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the Preferred Stock) automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  • F3 The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-10Liptak Vincent Paul Officer: General Counsel
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,50015.80
39,500

Derived: shares × price per share. Exact value 39500.00.

109,212Direct (D) No— Open filing 0002143905-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Chen Bihua Director · 10% ownerCormorant Asset Management, LP 10% ownerCormorant Global Healthcare Master Fund, LP 10% ownerCormorant Private Healthcare Fund III LP 10% ownerCormorant Private Healthcare Fund V LP 10% ownerCormorant Private Healthcare Fund VI, LP 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (23,904) — exercise price 16
Acquired (A)23,9040—23,904Direct (D) No
F9
  • F9 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
Open filing 0001231919-26-000852 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (23,904) — exercise price 16
Acquired (A)23,9040—23,904Direct (D) No
F1, F2
  • F1 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
  • F2 Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.
Open filing 0001282930-26-000008 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Liptak Vincent Paul Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (46,561) — exercise price 16
Acquired (A)46,5610—46,561Direct (D) No
F3
  • F3 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Open filing 0002143905-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Agrawal Sundeep Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (23,904) — exercise price 16
Acquired (A)23,9040—23,904Direct (D) No
F3
  • F3 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
Open filing 0001840599-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Oxnard Geoffrey Raymond Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (61,783) — exercise price 16
Acquired (A)61,7830—61,783Direct (D) No
F1
  • F1 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Open filing 0002144320-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Cui Jingrong Jean Director · Officer: President and CEO · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (676,205) — exercise price 16
Acquired (A)676,2050—676,205Direct (D) No
F4
  • F4 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Open filing 0001772259-26-000005 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Keyes Jason A Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (56,746) — exercise price 16
Acquired (A)56,7460—56,746Direct (D) No
F1
  • F1 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Open filing 0001678152-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Li Yishan Director · Officer: Executive Chairman · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (112,701) — exercise price 16
Acquired (A)112,7010—112,701Direct (D) No
F4
  • F4 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Open filing 0001772233-26-000005 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–39 of 39

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Cormorant Asset Management, LP Partly reported under another manager3,614,034 SH67,365,594 dollarsNot in the prior quarter’s filings read Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
ORBIMED ADVISORS LLC 2,714,279 SH50,594,161 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
PERCEPTIVE ADVISORS LLC 1,812,193 SH33,779,278 dollarsNot in the prior quarter’s filings read Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
Vivo Capital, LLC 1,493,740 SH27,843,314 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
DEERFIELD MANAGEMENT COMPANY, L.P. Partly reported under another manager1,446,000 SH26,953,440 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-120609 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager1,415,331 SH30,245,624 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager1,336,993 SH24,861,385 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager1,027,293 SH19,148,742 dollarsNot in the prior quarter’s filings read Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 433,302 SH8,076,749 dollarsNot in the prior quarter’s filings read Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
NEXTBio Capital Management LP 250,000 SH4,660,000 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-004969 Filed 2026-11-13 Dispute this row
SILVERARC CAPITAL MANAGEMENT, LLC 202,104 SH3,767,219 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002577 Filed 2026-11-12 Dispute this row
Opaleye Management Inc. 175,000 SH3,262,000 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager147,686 SH2,752,867 dollarsNot in the prior quarter’s filings read Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
a16z Capital Management, L.L.C. 125,000 SH2,330,000 dollarsNot in the prior quarter’s filings read Open filing 0001540358-26-000014 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager119,176 SH2,222,828 dollarsNot in the prior quarter’s filings read Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Monashee Investment Management LLC 80,000 SH1,491,200 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-004876 Filed 2026-11-06 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager73,691 SH1,373,600 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 60,281 SH1,123,638 dollarsNot in the prior quarter’s filings read Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC 55,000 SH1,025,200 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Ghisallo Capital Management LLC 50,000 SH932,000 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005189 Filed 2026-11-16 Dispute this row
Birchview Capital, LP 50,000 SH932,000 dollarsNot in the prior quarter’s filings read Open filing 0001618205-26-000005 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 45,818 SH854,048 dollarsNot in the prior quarter’s filings read Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager30,805 SH574,205 dollarsNot in the prior quarter’s filings read Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Walleye Capital LLC 28,659 SH534,204 dollarsNot in the prior quarter’s filings read Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
Squarepoint Ops LLC Partly reported under another manager23,150 SH431,516 dollarsNot in the prior quarter’s filings read Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager21,337 SH397,722 dollarsNot in the prior quarter’s filings read Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager17,200 SH320,608 dollarsNot in the prior quarter’s filings read Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager12,034 SH224,314 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 10,932 SH203,772 dollarsNot in the prior quarter’s filings read Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Jump Financial, LLC Partly reported under another manager10,223 SH190,557 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 10,194 SH190,016 dollarsNot in the prior quarter’s filings read Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 10,100 SH188,264 dollarsNot in the prior quarter’s filings read Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Aster Capital Management (DIFC) Ltd Partly reported under another manager4,822 SH89,882 dollarsNot in the prior quarter’s filings read Open filing 0002040915-26-000006 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager4,677 SH87,180 dollarsNot in the prior quarter’s filings read Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Vanguard Global Advisers, LLC 3,765 SH70,180 dollarsNot in the prior quarter’s filings read Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
Legal General Group Plc Partly reported under another manager1,612 SH30,836 dollarsNot in the prior quarter’s filings read Open filing 0001495115-26-000075 Filed 2026-11-16 Dispute this row
CITIGROUP INC Partly reported under another manager1,279 SH23,841 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
UBS Group AG Partly reported under another manager997 SH18,584 dollarsNot in the prior quarter’s filings read Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager512 SH10,941 dollarsNot in the prior quarter’s filings read Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Vivo Innovation Fund II Holdings, L.P. Common Stock, par value $0.0001 per share4.71,493,740.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-120149 Dispute this row
Vivo Innovation II, LLC Common Stock, par value $0.0001 per share4.71,493,740.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-120149 Dispute this row
Jingrong Jean Cui Common Stock, $0.0001 par value per share12.53,973,13809/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001193125-26-464174 Dispute this row
Yishan Li Common Stock, $0.0001 par value per share12.53,973,13809/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001193125-26-464174 Dispute this row
JANUS HENDERSON GROUP Ltd. Common Shares7.82,471,35409/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001274173-26-000283 Dispute this row
ORBIMED ADVISORS LLC Common Stock8.92,714,279.0008/10/2026 Filed 2026-08-18SCHEDULE 13DOpen filing 0000947871-26-000813 Dispute this row
OrbiMed Capital GP VIII LLC Common Stock8.92,714,279.0008/10/2026 Filed 2026-08-18SCHEDULE 13DOpen filing 0000947871-26-000813 Dispute this row
Vivo Innovation Fund II Holdings, L.P. Common Stock, par value $0.0001 per share5.51,681,240.0008/10/2026 Filed 2026-08-17SCHEDULE 13GOpen filing 0001213900-26-090726 Dispute this row
Vivo Innovation II, LLC Common Stock, par value $0.0001 per share5.51,681,240.0008/10/2026 Filed 2026-08-17SCHEDULE 13GOpen filing 0001213900-26-090726 Dispute this row
Perceptive Advisors LLC Common Stock, par value $0.00015.91,808,53308/07/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001193125-26-352634 Dispute this row
Joseph Edelman Common Stock, par value $0.00015.91,808,53308/07/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001193125-26-352634 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, par value $0.00015.91,808,53308/07/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001193125-26-352634 Dispute this row
Cormorant Global Healthcare Master Fund, LP Common Stock, $0.0001 par value per share3.13959,09008/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Global Healthcare GP, LLC Common Stock, $0.0001 par value per share3.13959,09008/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare Fund III, LP Common Stock, $0.0001 par value per share4.011,228,31508/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare GP III, LLC Common Stock, $0.0001 par value per share4.011,228,31508/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare Fund V, LP Common Stock, $0.0001 par value per share3.431,052,46008/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare GP V, LLC Common Stock, $0.0001 par value per share3.431,052,46008/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare Fund VI, LP Common Stock, $0.0001 par value per share1.22374,16908/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Private Healthcare GP VI, LLC Common Stock, $0.0001 par value per share1.22374,16908/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Cormorant Asset Management, LP Common Stock, $0.0001 par value per share11.793,614,03408/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row
Chen Bihua Common Stock, $0.0001 par value per share11.83,615,36208/06/2026 Filed 2026-08-13SCHEDULE 13DOpen filing 0000929638-26-003026 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,566,580 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020192,873
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to BlossomHill Therapeutics, Inc.